What You Should Know:
– Komodo Health, a leader in real-world healthcare data and analytics, has announced a significant expansion of its MapEnhance™ offering.
– The update empowers researchers and life sciences companies to gain a more comprehensive understanding of patient health by integrating social determinants of health (SDOH) data with clinical information.
Unveiling a Broader View of Patient Health
MapEnhance, available exclusively on Komodo’s AI-powered platform, offers a comprehensive suite of specialty data sets. These datasets, encompassing everything from lab results and genomics to electronic health records and mortality data, can be combined with Komodo’s Healthcare Map. This integrated approach facilitates in-depth research across various disease areas while considering the social and environmental factors impacting patient outcomes.
Expanded Social Determinants Insights
Komodo is significantly expanding its SDOH intelligence, allowing users to analyze how social, economic, and environmental factors influence patient health alongside clinical data. This census-level visibility empowers researchers to paint a more complete picture of patient well-being.
Strengthened Partnerships Drive Deeper Insights
MapEnhance boasts a robust network of specialty data partners, including GeneDx and COTA Healthcare (newly added). The partnership with GeneDx grants access to a vast de-identified genetic rare disease dataset, aiding in drug development and clinical trial enrollment. COTA’s deep clinical cancer information, combined with other MapEnhance data, delivers valuable insights to life sciences researchers throughout the cancer care journey.
Proprietary Data Assets Enhance Understanding
In addition to partner data, Komodo has expanded its MapEnhance library with exclusive, in-house data assets. These assets, meticulously curated by Komodo’s data science team, encompass clinical observations, lab results, self-identified race and ethnicity information, and more. This enriched data landscape enhances the visibility of patient populations and clinical encounters within the Healthcare Map.
Real-World Impact for Researchers
Researchers at leading institutions and life sciences companies have leveraged MapEnhance to power numerous studies presented at ISPOR 2024. These studies explored critical disease trends in women’s health, oncology, mental health, and more. Notably, a study ranked among the top 5% at ISPOR examined the impact of an FDA safety initiative on clozapine users by combining Healthcare Map data with MapEnhance lab insights.
Focus on Quality and Security
All MapEnhance data is de-identified and ready for immediate use, ensuring rapid access to valuable insights. Komodo employs rigorous processes for data de-duplication, normalization, analysis, and correction, guaranteeing the integrity of the Healthcare Map.
Komodo’s enhanced MapEnhance platform empowers researchers to unlock a deeper understanding of patient health, paving the way for advancements in healthcare research and improved patient outcomes.
“In a landscape where healthcare costs are skyrocketing, the demand for accurate, nuanced, and unbiased data has never been more critical,” said Brad Kelley, General Manager of MapEnhance, Komodo Health. “By adding insights into the social determinants of health along with oncology and rare disease genomics data, we are strengthening the ability of MapEnhance to power insights that can lead to important commercial strategies and medical breakthroughs — and we’re doing it with greater speed and accuracy than anything else on the market today.”
